FI92880B - Bestämning av degradation av typ III kollagen - Google Patents
Bestämning av degradation av typ III kollagen Download PDFInfo
- Publication number
- FI92880B FI92880B FI895267A FI895267A FI92880B FI 92880 B FI92880 B FI 92880B FI 895267 A FI895267 A FI 895267A FI 895267 A FI895267 A FI 895267A FI 92880 B FI92880 B FI 92880B
- Authority
- FI
- Finland
- Prior art keywords
- antibody
- type iii
- iii collagen
- marker
- antigen
- Prior art date
Links
- 102000001187 Collagen Type III Human genes 0.000 title claims abstract description 40
- 108010069502 Collagen Type III Proteins 0.000 title claims abstract description 40
- 230000015556 catabolic process Effects 0.000 title abstract description 8
- 238000006731 degradation reaction Methods 0.000 title abstract description 8
- 238000000034 method Methods 0.000 claims abstract description 24
- 239000007857 degradation product Substances 0.000 claims abstract description 9
- 230000011382 collagen catabolic process Effects 0.000 claims description 7
- 239000000047 product Substances 0.000 claims description 4
- 239000003550 marker Substances 0.000 claims 7
- 239000007787 solid Substances 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 abstract description 4
- 210000002700 urine Anatomy 0.000 abstract description 3
- 230000001900 immune effect Effects 0.000 abstract description 2
- 239000007788 liquid Substances 0.000 abstract 2
- 206010046798 Uterine leiomyoma Diseases 0.000 abstract 1
- 201000010260 leiomyoma Diseases 0.000 abstract 1
- 201000007954 uterine fibroid Diseases 0.000 abstract 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 102000008186 Collagen Human genes 0.000 description 7
- 108010035532 Collagen Proteins 0.000 description 7
- 229920001436 collagen Polymers 0.000 description 7
- 239000000243 solution Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000003127 radioimmunoassay Methods 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 210000002808 connective tissue Anatomy 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 3
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 3
- 239000001099 ammonium carbonate Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229940044173 iodine-125 Drugs 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 238000005191 phase separation Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 208000010485 smooth muscle tumor Diseases 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229960001479 tosylchloramide sodium Drugs 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- AYCBEBLKWYWMTN-UHFFFAOYSA-N CC1=C(C(=O)N(C1=O)C)C(C)(C)CCC2=CC=CC=C2 Chemical compound CC1=C(C(=O)N(C1=O)C)C(C)(C)CCC2=CC=CC=C2 AYCBEBLKWYWMTN-UHFFFAOYSA-N 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102100030152 Complement C1r subcomponent-like protein Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 101100326463 Homo sapiens C1RL gene Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 238000004401 flow injection analysis Methods 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 230000008364 tissue synthesis Effects 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Laminated Bodies (AREA)
Claims (5)
1. Förfarande för bestämning av degradationsprodukter av typ III kollagen, kännetecknat därav, att ett prov, som kan innehälla sädana produkter, bringas i kontakt med en antikropp, som är specifik mot den amino-terminala telopeptiden av typ III kollagen, och med en markör, under sädana förhällanden, att markören binds i en mängd beroende pä mängden av degraderingsprodukter av typ III kollagen närvarande i provet, och därefter bes-täms den obundna och/eller den bundna markören, som visar mängden av degraderingsprodukter av typ III kollagen närvarande i provet.
2. Förfarande enligt patentkravet 1, kännetecknat därav, att den märkta aminoterminala telopeptiden av typ III kollagen samt provet, bäda bringas i kontakt med den nämnda antikroppen, och det sk bildade antigen-antikropp-komplexet separeras frän de okomplexerade utgängsprodukterna och den komplexerade eller okomplexerade markören bestäms.
3. Förfarande enligt patentkravet 2, kännetecknat därav, att antigen-antikropp-komplexet bringas i kontakt med en annan antikropp, som är specifik mot den första antikroppen, och det sk bildade antigen-antikropp-antikropp-komplexet separeras frän de okomplexerade ut-gängsprodukterna.
4. Förfarande enligt patentkravet 2 eller 3, kännetecknat därav, att markören är en radioaktiv markör, en enzymmarkör eller en fluorescerande markör.
5. Förfarande enligt nägot av patentkraven 2-4, II 92680 kännetecknat därav, att den första antikrop-pen eller den andra antikroppen är bunden tili ett fast underlag och antigen-antikropp- eller antigen-antikropp-antikropp-komplexet separeras frän den lösning, i vilken kontakten sker, genom att separera det fasta underlaget.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI895267A FI92880C (sv) | 1987-05-08 | 1989-11-06 | Bestämning av degradation av typ III kollagen |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8710925A GB2205643B (en) | 1987-05-08 | 1987-05-08 | Type iii collagen degradation assay |
| GB8710925 | 1987-05-08 | ||
| PCT/FI1988/000066 WO1988008980A1 (en) | 1987-05-08 | 1988-05-02 | Type iii collagen degradation assay |
| FI8800066 | 1988-05-02 | ||
| FI895267A FI92880C (sv) | 1987-05-08 | 1989-11-06 | Bestämning av degradation av typ III kollagen |
| FI895267 | 1989-11-06 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI895267A0 FI895267A0 (sv) | 1989-11-06 |
| FI92880B true FI92880B (sv) | 1994-09-30 |
| FI92880C FI92880C (sv) | 1995-01-10 |
Family
ID=10617032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI895267A FI92880C (sv) | 1987-05-08 | 1989-11-06 | Bestämning av degradation av typ III kollagen |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US5342756A (sv) |
| EP (1) | EP0362235B1 (sv) |
| JP (1) | JPH0814577B2 (sv) |
| AT (1) | ATE80464T1 (sv) |
| DE (1) | DE3874530T2 (sv) |
| DK (1) | DK557089A (sv) |
| FI (1) | FI92880C (sv) |
| GB (1) | GB2205643B (sv) |
| NO (1) | NO890071L (sv) |
| WO (1) | WO1988008980A1 (sv) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6010862A (en) * | 1987-11-06 | 2000-01-04 | Washington Research Foundation | Methods of detecting collagen type III degradation in vivo |
| US5300434A (en) * | 1987-11-06 | 1994-04-05 | Washington Research Foundation | Hybridoma cell line producing an antibody to type-I collagen amino-terminal telopeptide |
| US5320970A (en) * | 1987-11-06 | 1994-06-14 | Washington Research Foundation | Detection of collagen degradation in vivo |
| US5962639A (en) * | 1987-11-06 | 1999-10-05 | Washington Research Foundation | Synthetic peptides corresponding to telopeptide sequences of cross-linked type I collagen metabolites |
| US6027903A (en) * | 1987-11-06 | 2000-02-22 | Washington Research Foundation | Kit for detecting analyte indicative of type I collagen resorption in vivo |
| US5702909A (en) * | 1987-11-06 | 1997-12-30 | Washington Research Foundation | Methods of detecting collagen type II degradation in vivo |
| US4973666A (en) | 1987-11-06 | 1990-11-27 | Washington Research Foundation | Peptide fragments containing HP and LP cross-links |
| US6153732A (en) * | 1987-11-06 | 2000-11-28 | Washington Research Foundation | Kit for detecting analyte indicative of type II collagen resorption in vivo |
| GB9105893D0 (en) * | 1991-03-20 | 1991-05-08 | Orion Yhtymae Oy | Bone resorption assay based on a peptide liberated during collagen degradation |
| CA2152667C (en) * | 1992-12-28 | 2003-02-11 | David J. Baylink | Bone resorption assay |
| US6110689A (en) | 1994-01-21 | 2000-08-29 | Osteometer A/S | Method of assaying collagen fragments in body fluids, a test kit and means for carrying out the method and use of the method to diagnose the presence of disorders associated with the metabolism of collagen |
| GB9506050D0 (en) | 1995-03-24 | 1995-05-10 | Osteometer A S | Assaying collagen fragments in body fluids |
| AU3746295A (en) | 1994-10-17 | 1996-05-06 | Osteometer Biotech As | Estimation of the fragmentation pattern of collagen in body fluids and the diagnosis of disorders associated with the metabolism of collagen |
| DE19518232A1 (de) * | 1995-05-12 | 1996-11-14 | Ruediger Dr Schade | Aviäre, vitelline, gegen Stützgewebe gerichtete Antikörper |
| US6107047A (en) * | 1996-03-21 | 2000-08-22 | Osteometer Biotech A/S | Assaying protein fragments in body fluids |
| GB9617616D0 (en) | 1996-08-22 | 1996-10-02 | Osteometer Biotech As | Assaying protein fragments in body fluids |
| EP0829724A1 (en) * | 1996-09-17 | 1998-03-18 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | Assay for detecting collagen degradation |
| DE69705423T2 (de) | 1996-12-09 | 2002-05-16 | Osteometer Biotech As Herlev | Sandwichtest zum nachweis von kollagenfragmenten |
| US6117646A (en) * | 1997-09-22 | 2000-09-12 | Osteometer Biotech A/S | Assaying protein fragments in body fluids |
| JP4436972B2 (ja) | 1998-06-19 | 2010-03-24 | ワシントン リサーチ ファンデーション | 軟骨吸収アッセイ |
| US6602980B1 (en) | 1998-06-19 | 2003-08-05 | Washington Research Foundation | Collagen type III synthetic peptides for collagen resorption assays |
| US6916903B2 (en) | 1998-06-19 | 2005-07-12 | Washington Research Foundation | Collagen type III synthetic peptides for collagen resorption assays |
| US6348320B1 (en) | 1998-06-19 | 2002-02-19 | Washington Research Foundation | Cartilage resorption assays measuring type II collagen fragments |
| DE69920981T2 (de) * | 1999-06-17 | 2005-07-21 | Washington Research Foundation, Seattle | Knorpelresorptionsassays |
| US7405037B2 (en) * | 2004-05-07 | 2008-07-29 | Lonza Walkersville, Inc. | Methods and tools for detecting collagen degradation |
| CN101467045A (zh) * | 2006-06-15 | 2009-06-24 | 皇家飞利浦电子股份有限公司 | 通过测定结合和未结合的标记增加分析物检测的专一性 |
| FR2908413B1 (fr) | 2006-11-15 | 2009-03-06 | Synarc Soc Par Actions Simplif | Marqueur specifique d'une degradation oxydative de tissus contenant du collagene de type iii,moyens et methodes,kits de diagnostic de suivi ou de pronostic des pathologies ciblees par ce marqueur. |
| TWI395593B (zh) | 2008-03-06 | 2013-05-11 | Halozyme Inc | 可活化的基質降解酵素之活體內暫時性控制 |
| WO2009153783A1 (en) * | 2008-06-16 | 2009-12-23 | Mor Research Applications Ltd. | Monitoring skin metabolism products for evaluating burn injury |
| US20110229451A2 (en) * | 2009-03-06 | 2011-09-22 | Halozyme, Inc. | Temperature sensitive mutants of matrix metalloproteases and uses thereof |
| US20150196625A9 (en) | 2013-01-07 | 2015-07-16 | Rudolph D. Paladini | Metal Sensitive Mutants of Matrix Metalloproteases and uses thereof |
| US20240003906A1 (en) * | 2020-04-16 | 2024-01-04 | Nordic Bioscience A/S | Biomarker of Fibrosis |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4628027A (en) * | 1982-05-19 | 1986-12-09 | Molecular Engineering Associates, Ltd. | Vitro diagnostic methods using monoclonal antibodies against connective tissue proteins |
| CA1251729A (en) * | 1982-05-19 | 1989-03-28 | Steffen Gay | In vitro diagnostic methods using monoclonal antibodies against connective tissue proteins |
-
1987
- 1987-05-08 GB GB8710925A patent/GB2205643B/en not_active Expired - Fee Related
-
1988
- 1988-05-02 DE DE8888904225T patent/DE3874530T2/de not_active Expired - Fee Related
- 1988-05-02 JP JP63503924A patent/JPH0814577B2/ja not_active Expired - Fee Related
- 1988-05-02 US US07/435,369 patent/US5342756A/en not_active Expired - Fee Related
- 1988-05-02 EP EP88904225A patent/EP0362235B1/en not_active Expired - Lifetime
- 1988-05-02 WO PCT/FI1988/000066 patent/WO1988008980A1/en active IP Right Grant
- 1988-05-02 AT AT88904225T patent/ATE80464T1/de not_active IP Right Cessation
-
1989
- 1989-01-06 NO NO89890071A patent/NO890071L/no unknown
- 1989-11-06 FI FI895267A patent/FI92880C/sv not_active IP Right Cessation
- 1989-11-08 DK DK557089A patent/DK557089A/da not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| GB8710925D0 (en) | 1987-06-10 |
| DE3874530T2 (de) | 1993-02-04 |
| NO890071D0 (no) | 1989-01-06 |
| GB2205643B (en) | 1991-03-13 |
| GB2205643A (sv) | 1988-12-14 |
| JPH02503823A (ja) | 1990-11-08 |
| DE3874530D1 (de) | 1992-10-15 |
| DK557089D0 (da) | 1989-11-08 |
| US5342756A (en) | 1994-08-30 |
| FI895267A0 (sv) | 1989-11-06 |
| ATE80464T1 (de) | 1992-09-15 |
| EP0362235A1 (en) | 1990-04-11 |
| NO890071L (no) | 1989-01-06 |
| EP0362235B1 (en) | 1992-09-09 |
| JPH0814577B2 (ja) | 1996-02-14 |
| DK557089A (da) | 1989-11-08 |
| WO1988008980A1 (en) | 1988-11-17 |
| FI92880C (sv) | 1995-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI92880B (sv) | Bestämning av degradation av typ III kollagen | |
| JP2886728B2 (ja) | コラーゲン分解時に放出されるペプチドを基準にした骨吸収分析 | |
| JPS63126496A (ja) | プロコラ−ゲン・ペプチド（３型）特異抗血清の製法 | |
| Gross et al. | Isolation, characterization, and distribution of an unusual pancreatic human secretory protein. | |
| JP3137676B2 (ja) | Ｉ型プロコラーゲンのｃ末端プロペプチドの免疫学的定量法 | |
| JP2801212B2 (ja) | タイプ▲ｉｉｉ▼プロコラーゲンのプロペプチドに対する抗体およびそれを用いるアッセイ法 | |
| JPH05255390A (ja) | オリゴペプチド接合体 | |
| JP3245052B2 (ja) | Ｉ型プロコラーゲンのアミノ末端プロペプチドに対する抗体およびそれを用いるアッセイ法 | |
| JPH083486B2 (ja) | 体液中の基底膜コラーゲンの測定法及び基底膜コラーゲン―ドメインｎｃ１に対する抗体の検出法 | |
| JP2532559B2 (ja) | ヒトおよび動物組織からの基底膜タンパクの単離方法 | |
| US6008325A (en) | Antibody to aminoterminal propeptide of type 1 procollagen | |
| US5177020A (en) | Method for the immunological determination of heparan sulfate-proteoglycan and process for the preparation and purification of heparan sulfate-proteoglycan suitable for this purpose from tissues containing basal membrane | |
| JP3433245B2 (ja) | ビタミンｂ１２を決定するためのイムノアッセイ、ならびにそのための試薬およびキット | |
| JPH04134097A (ja) | ラミニン フラグメント | |
| JPH0785085B2 (ja) | フイブロネクチン測定試薬 | |
| WO1989011097A1 (en) | Method for assaying chondrocalcine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or assigment of application |
Owner name: ORION-YHTYMAE OY |
|
| BB | Publication of examined application | ||
| FG | Patent granted |
Owner name: ORION DIAGNOSTICA OY |
|
| MA | Patent expired |